Harmony Biosciences Receives 'Hold' Rating from Analysts

Twelve analysts cover the biopharmaceutical company, with mixed recommendations on the stock.

Apr. 17, 2026 at 6:25am

Got story updates? Submit your updates here. ›

A high-contrast, close-up image of gears, levers, and other industrial banking equipment, representing the institutional and systemic nature of the financial industry.The complex machinery and systems that power the financial markets remain a source of uncertainty and scrutiny for investors.Plymouth Meeting Today

Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) have received an average 'Hold' rating from the twelve analysts covering the company, according to Marketbeat Ratings. The ratings include two 'Sell' recommendations, five 'Hold' ratings, four 'Buy' ratings, and one 'Strong Buy' rating. The analysts' average 12-month price target for the stock is $42.67.

Why it matters

Harmony Biosciences is a commercial-stage biopharmaceutical company focused on developing therapies for rare neurological and endocrine diseases. The mixed analyst ratings and price targets reflect the challenges and uncertainties the company faces as it works to commercialize its flagship product, WAKIX, and grow its business.

The details

Several analysts have recently weighed in on Harmony Biosciences. Wall Street Zen downgraded the stock from 'Buy' to 'Hold', while Needham & Company LLC reduced its price target from $46 to $44. Bank of America and Deutsche Bank Aktiengesellschaft also downgraded the stock and lowered their price targets.

  • Harmony Biosciences reported its latest quarterly earnings on February 24, 2026.
  • The company's stock opened at $29.42 on Friday, April 17, 2026.

The players

Harmony Biosciences Holdings, Inc.

A commercial-stage biopharmaceutical company focused on developing therapies for rare neurological and endocrine diseases. The company's flagship product is WAKIX, the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S. FDA.

Wall Street Zen

An equity research firm that downgraded Harmony Biosciences from 'Buy' to 'Hold' rating.

Needham & Company LLC

An investment banking and asset management firm that reduced its price target for Harmony Biosciences from $46 to $44.

Bank of America

A multinational investment bank and financial services company that downgraded Harmony Biosciences and lowered its price target.

Deutsche Bank Aktiengesellschaft

A German multinational investment bank and financial services company that downgraded Harmony Biosciences and set a new price target.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The mixed analyst ratings and price targets for Harmony Biosciences reflect the challenges the company faces as it works to commercialize its rare disease drug and grow its business. Investors will be closely watching the company's progress in the coming quarters.